His main research concerns Epidermal growth factor receptor, Cancer research, Growth factor receptor, Monoclonal antibody and Epidermal growth factor. His work deals with themes such as Signal transduction, Mutant, Downregulation and upregulation and Monoclonal, which intersect with Epidermal growth factor receptor. His study of Glioma is a part of Cancer research.
The concepts of his Monoclonal antibody study are interwoven with issues in Molecular biology and Transplantation. His Molecular biology research incorporates elements of Immunohistochemistry and Epitope, Antibody. He has researched Epidermal growth factor in several fields, including Endocrinology and Growth factor.
Cancer research, Epidermal growth factor receptor, Molecular biology, Antibody and Glioma are his primary areas of study. His Cancer research study combines topics from a wide range of disciplines, such as Cancer, Protein kinase B, Signal transduction, Receptor tyrosine kinase and Growth factor receptor. His research integrates issues of Tyrosine kinase, Epidermal growth factor, Transplantation and Panitumumab in his study of Epidermal growth factor receptor.
Terrance Grant Johns combines subjects such as Cancer cell, Receptor, Biochemistry, Epitope and Monoclonal antibody with his study of Molecular biology. His studies in Receptor integrate themes in fields like Cell culture, Mutant and Cell biology. His Glioma research is multidisciplinary, incorporating elements of Medulloblastoma, Pathology, Immunology, Stem cell and In vivo.
His scientific interests lie mostly in Cancer research, Medulloblastoma, Stem cell, Glioma and Cancer. His Cancer research research includes elements of Cell culture, DNA damage, Receptor, Receptor tyrosine kinase and Antibody. His research integrates issues of Clinical trial and Oncology in his study of Medulloblastoma.
His study on Glioma is mostly dedicated to connecting different topics, such as Epidermal growth factor receptor. The Epidermal growth factor receptor study combines topics in areas such as Matuzumab, Cetuximab, Panitumumab and Pineoblastoma. His Cancer research is multidisciplinary, incorporating perspectives in Soft tissue sarcoma, Transcription factor, Microtubule and OLIG2.
Terrance Grant Johns mostly deals with Cancer research, Stem cell, Growth factor receptor, Immunohistochemistry and ERBB4. The various areas that Terrance Grant Johns examines in his Cancer research study include Cell cycle checkpoint, DNA damage, Chemotherapy, Cisplatin and Apoptosis. He interconnects Tubulin, Microtubule, Glioblastoma and Cancer in the investigation of issues within Stem cell.
His work carried out in the field of Growth factor receptor brings together such families of science as Angiogenesis, Tyrosine kinase, Oncogene and Receptor tyrosine kinase, Phosphorylation. Terrance Grant Johns connects Dystroglycan with Glioma in his research. His studies in Glioma integrate themes in fields like Central nervous system, Compartment, Receptor, Extracellular matrix and Antibody.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma
Maria-del-Mar Inda;Rudy Bonavia;Akitake Mukasa;Akitake Mukasa;Yoshitaka Narita.
Genes & Development (2010)
Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis
C. C. A. Bernard;T. G. Johns;A. Slavin;M. Ichikawa.
Journal of Molecular Medicine (1997)
Targeting the ERBB family in cancer: couples therapy
Niall Tebbutt;Mikkel Wandahl Pedersen;Terrance Grant Johns.
Nature Reviews Cancer (2013)
Growth Suppression of Intracranial Xenografted Glioblastomas Overexpressing Mutant Epidermal Growth Factor Receptors by Systemic Administration of Monoclonal Antibody (mAb) 806, a Novel Monoclonal Antibody Directed to the Receptor
Kazuhiko Mishima;Terrance G. Johns;Rodney B. Luwor;Andrew M. Scott.
Cancer Research (2001)
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors
Andrew M Scott;Fook-Thean Lee;Niall Tebbutt;Rebecca Herbertson.
Proceedings of the National Academy of Sciences of the United States of America (2007)
The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered
Hui K Gan;Anna Nada Cvrljevic;Terrance Grant Johns.
FEBS Journal (2013)
The Structure and Function of Myelin Oligodendrocyte Glycoprotein
Terrance G. Johns;Claude C. A. Bernard.
Journal of Neurochemistry (1999)
A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor.
Achim A Jungbluth;Elisabeth Stockert;H J Su Huang;Vincent P Collins.
Proceedings of the National Academy of Sciences of the United States of America (2003)
Targeted drug delivery using genetically engineered diatom biosilica
Bahman Delalat;Vonda C Sheppard;Soraya Rasi Ghaemi;Shasha Rao.
Nature Communications (2015)
Validation of the MTT dye assay for enumeration of cells in proliferative and antiproliferative assays.
B E Loveland;T G Johns;I R Mackay;F Vaillant.
Biochemistry international (1992)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: